Improving the flexibility of cell line development through utilization of platform approaches and suitable partnerships can reduce potential bottlenecks in the development pathway of novel biologics.
Simon Keen
Advertisement
Simon Keen, vice president Cell Line Development, Abzena
Articles by Simon Keen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
